Radio-chemotherapy in anal cancer: Institutional experience at a large radiation oncology center in Chile

Russo, Moisés; Ovalle, V.

doi:10.1016/j.rpor.2014.02.001

Cited by 2 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Today, a vast amount of clinical experience from single‐institution trials as well as prospective clinical trials on primary organ preserving treatment is available . Multimodality organ‐preservation treatment has become the treatment of choice for many tumor entities . Nevertheless, the issue of conservative treatments versus cystectomy for bladder cancer remains controversial.…”

Section: Introductionmentioning

confidence: 99%

Long-Term Experience of Chemoradiotherapy Combined with Deep Regional Hyperthermia for Organ Preservation in High-Risk Bladder Cancer (Ta, Tis, T1, T2)

et al. 2019

View full text Add to dashboard Cite

Background. The aim of this study was to evaluate the efficacy and safety of chemoradiotherapy (RCT) combined with regional deep hyperthermia (RHT) of high-risk bladder cancer after transurethral resection of bladder tumor (TUR-BT). Materials and methods. Between 1982 and 2016, 369 patients with pTa, pTis, pT1, and pT2 cN0-1 cM0 bladder cancer were treated with a multimodal treatment after TUR-BT. All patients received radiotherapy (RT) of the bladder and regional lymph nodes. RCT was administered to 215 patients, RCT + RHT was administered to 79 patients, and RT was used in 75 patients. Treatment response was evaluated 4-6 weeks after treatment with TUR-BT. Results. Complete response (CR) overall was 83% (290/351), and in treatment groups was RT 68% (45/66), RCT 86% (178/208), and RCT + RHT 87% (67/77). CR was significantly improved by concurrent RCT compared with RT (odds ratio [OR], 2.32; 95% confidence interval [CI], 1.05-5.12; p = .037), less influenced by hyperthermia (OR, 2.56; 95% CI, 0.88-8.00; p = .092). Overall survival (OS) after RCT was superior to RT (hazard ratio [HR], 0.7; 95% CI, 0.50-0.99; p = .045). Five-year OS from unadjusted Kaplan-Meier estimates was RCT 64% versus RT 45%. Additional RHT increased 5-year OS to 87% (HR, 0.32; 95% CI, 0.18-0.58; p = .0001). RCT + RHT compared with RCT showed a significantly better bladder-preservation rate (HR, 0.13; 95% CI, 0.03-0.56; p = .006). Median follow-up was 71 months. The median number of RHT sessions was five. Conclusion. The multimodal treatment consisted of a maximal TUR-BT followed by RT; concomitant platinum-based chemotherapy combined with RHT in patients with high-grade bladder cancer improves local control, bladder-preservation rate, and OS. It offers a promising alternative to surgical therapies like radical cystectomy. The Oncologist 2019;24:e1341-e1350 Implications for Practice: Radical cystectomy with appropriate lymph node dissection has long represented the standard of care for muscle-invasive bladder cancer in medically fit patients, despite many centers reporting excellent long-term results for bladder preserving strategies. This retrospective analysis compares different therapeutic modalities in bladder-preservation therapy. The results of this study show that multimodal treatment consisting of maximal transurethral resection of bladder tumor followed by radiotherapy, concomitant platinum-based chemotherapy combined with regional deep hyperthermia in patients with Ta, Tis, T1-2 bladder carcinomas improves local control, bladder-preservation rate, and survival. More importantly, these findings offer a promising alternative to surgical therapies like radical cystectomy. The authors hope that, in the future, closer collaboration between urologists and radiotherapists will further improve treatments and therapies for the benefit of patients.Cumulative estimated DFS for RCT (40%; 95% CI, 34%-47% and 24%; 95% CI, 18%-30%) was superior to RT (20%; 95% Merten, Ott, Haderlein et al. e1345Abbreviations: CI, confidence interval; cis, associate...

show abstract

Section: Introductionmentioning

confidence: 99%

Long-Term Experience of Chemoradiotherapy Combined with Deep Regional Hyperthermia for Organ Preservation in High-Risk Bladder Cancer (Ta, Tis, T1, T2)

et al. 2019

View full text Add to dashboard Cite

show abstract

“…With a median follow-up of 56 months, with a minimum of at least 24 months, at 5 years the authors found both OS and DFS of 45%. 33 In our study, we analyzed a population of 27 patients affected by anal carcinoma treated with primary radiochemotherapy based on 5-FU associated with MMC or CDDP (FUMIR vs. PLAFUR schedules).…”

Section: Discussionmentioning

confidence: 99%

Radiochemotherapy in Anal Cancer: cCR, clinical outcomes and quality of life using two different treatment schedules

Santo

Trignani

Neri

et al. 2015

Reports of Practical Oncology & Radiotherapy

View full text Add to dashboard Cite

show abstract

Radio-chemotherapy in anal cancer: Institutional experience at a large radiation oncology center in Chile

Abstract: Our findings show that results at the Instituto de Radiomedicina in Chile are comparable to published literature. Dismal results in stage IIIb cases indicate much work remains in therapies to achieve loco-regional control in locally advanced cases.

Cited by 2 publications

References 9 publications

Long-Term Experience of Chemoradiotherapy Combined with Deep Regional Hyperthermia for Organ Preservation in High-Risk Bladder Cancer (Ta, Tis, T1, T2)

Long-Term Experience of Chemoradiotherapy Combined with Deep Regional Hyperthermia for Organ Preservation in High-Risk Bladder Cancer (Ta, Tis, T1, T2)

Radiochemotherapy in Anal Cancer: cCR, clinical outcomes and quality of life using two different treatment schedules

Contact Info

Product

Resources

About